Workit Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual addiction treatment platform for alcohol and opioid use disorder, Ann Arbor MI, raised $118M+. Combines medication-assisted treatment with digital coaching.
About
Workit Health is an Ann Arbor, Michigan-based virtual addiction treatment company founded in 2015 that provides evidence-based treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) through a telehealth platform. The company has raised over $118 million and operates in multiple US states, delivering medication-assisted treatment (MAT) including buprenorphine prescribing alongside behavioral health coaching and peer support — all accessible from a member's smartphone.\n\nWorkit Health's model addresses the primary barriers to addiction treatment: stigma, geographic access, and cost. By delivering care via telehealth, the platform reaches patients in rural areas and communities where addiction specialists are scarce. The company accepts Medicaid in multiple states, making treatment accessible to lower-income patients who are disproportionately impacted by the opioid crisis. Clinicians on the platform conduct initial assessments by video, prescribe medications electronically, and monitor patient progress through regular virtual check-ins and app-based engagement tools.\n\nThe platform includes a structured digital program with skills-based modules covering triggers, coping strategies, and recovery maintenance, delivered alongside clinical care. Workit Health competes with Bicycle Health, Ophelia, and Boulder Care in the virtual MAT market. The company has expanded to serve employers and health plans as well as direct consumers, positioning it as both a consumer-facing addiction recovery resource and a value-based care solution for payers managing high-cost substance use disorder populations.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.